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Abstract RNA aptamers that bind to the Ras-binding domain
(RBD) of a proto-oncogene product, Raf-1, were isolated from a
pool of random sequences using a glutathione S-transferase-fused
RBD (GST-RBD). The RNA molecules bind to the GST-RBD,
but not to GST, with dissociation constants of about 300 nM. In
contrast, these RNA aptamers do not bind to the Ras-binding
domain of the RGL protein, which is also known to be activated
by Ras. The aptamers actually compete with Ras for binding to
the Raf-1 RBD. The anti-Raf-1 aptamers may be used to
specifically inhibit the Ras-Raf interaction in the complicated
signaling network in mammalian cells.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Raf-1, the product of a proto-oncogene, c-raf-1, is a 74-kDa
cytoplasmic serine/threonine protein kinase that regulates
mammalian cell proliferation and di¡erentiation. The Raf
family kinases (Raf-1, A-Raf, and B-Raf) phosphorylate and
activate MAPK/ERK kinases (MEKs), which in turn phos-
phorylate extracellular signal-regulated kinases (ERKs) be-
longing to the mitogen-activated protein kinase (MAPK) fam-
ily [1,2]. The Raf kinases are activated either through
interaction with the Ras proto-oncogene product on the plas-
ma membrane [3^8] or by Ras-independent mechanisms
[9,10]. Ras belongs to a family of small GTP-binding proteins,
and cycles between the GTP- and GDP-bound forms [11,12].
The GTP-bound Ras physically associates with residues 51^
131 of Raf-1 (the Ras-binding domain, RBD) [6,13] with a Kd
value of 18 nM [14]. In addition to Raf-1, the GTP-bound
Ras can bind various downstream e¡ectors, such as the gua-
nine nucleotide dissociation stimulators for the Ral protein,
RalGDS and RGL, through the same binding interface as
that for the Raf-1 binding [15^18].
The molecular mechanisms of the cellular signaling involv-
ing these proteins are therefore complicated, and it is impor-
tant to elucidate the role of each protein-protein interaction.
Accordingly, there have been many e¡orts to selectively inhib-
it the Ras-Raf signaling pathway. For instance, dominant-
negative Raf-1 mutants, which bind to Ras but lack the kinase
activity, prevent the Ras-dependent activation of the wild-type
Raf-1 [19]. However, these Raf-1 mutants prevent the GTP-
bound Ras from interacting with any downstream e¡ectors. In
addition, monoclonal antibodies that bind to an epitope in the
Raf-1 kinase domain inhibit both the Ras-dependent and
-independent Raf-activation mechanisms [20]. Therefore, it is
worth while to develop a selective inhibitor of only the Ras-
Raf interaction. Note that the two proto-oncogene products,
Ras and Raf-1, are good candidates for targets of anti-cancer
drug development.
It is possible to isolate RNA or DNA molecules (aptamers)
with high a⁄nity for a given protein by in vitro selection
[21,22]. As for proteins related to cellular signaling pathways,
aptamers targeting the LII isozyme of protein kinase C and
Yersinia protein tyrosine phosphatase, for example, have been
isolated and demonstrated to inhibit the enzyme activities
[23,24]. In the present study, by in vitro selection, we isolated
RNA aptamers to the RBD of Raf-1, which actually inhibited
the interaction between the two proteins, Ras and the RBD of
Raf-1.
2. Materials and methods
2.1. Protein puri¢cation
The Raf-1 RBD (amino acid residues 51^131 of human c-Raf-1)
fused to glutathione S-transferase (GST) (designated GST-RBD) was
expressed in Escherichia coli (strains BL21 and BL21DE3) and was
puri¢ed by glutathione-Sepharose 4B (Amersham Pharmacia Biotech)
and Poros HQ (PerSeptive Biosystems) column chromatography [25].
The GST-fusion form of the RGL RBD (amino acid residues 632^734
of human RGL) was expressed in E. coli BL21, and was puri¢ed by
glutathione-Sepharose 4B column chromatography and Resource Q
FPLC (Amersham Pharmacia Biotech) [26]. The wild-type human Ha-
Ras protein was prepared from an E. coli overproducing strain, and
was puri¢ed by DEAE-Sephacel and Sephadex G-75 column chroma-
tography followed by Resource Q FPLC [25,27,28]. The ¢nal protein
preparations were con¢rmed to be homogeneous by SDS-PAGE with
Coomassie brilliant blue and silver staining.
2.2. In vitro selection
For selection, a pool of RNAs with 60 random nucleotides £anked
by de¢ned sequences (Fig. 1) was transcribed from the PCR products
of the synthetic DNA templates. The RNAs were heated at 75‡C for
3 min, then cooled on ice, and incubated in a binding bu¡er (phos-
phate-bu¡ered saline containing 5 mM MgCl2, bu¡er A) together
with the GST-RBD of Raf-1 and a matrix (glutathione-Sepharose
4B) at 4‡C for 1 h. The matrix was washed with a bu¡er (20 mM
Tris-HCl pH 7.5, 5 mM MgCl2, and 150 mM NaCl, bu¡er B) and the
RNAs were then eluted with distilled H2O by boiling. Prior to the
incubation with the Raf-1 GST-RBD (from the 3rd to the 13th round)
and also after the elution (from the 7th to the 13th round), the RNAs
were passed through a matrix bearing only GST, to eliminate the
RNAs that bind to GST and/or the matrix. The eluted RNAs were
reverse-transcribed and ampli¢ed by PCR. The RNA pool for the
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next round was prepared by in vitro transcription from the ampli¢ed
cDNA. From the 1st to the 13th round, the above selection procedure
was applied. After 13 rounds, the selection was continued using a
¢lter-binding method [24]. The renatured RNAs and the Raf-1
GST-RBD were incubated in bu¡er A at 37‡C for 60 min. The
RNAs bound to the Raf-1 GST-RBD were separated from the un-
bound RNAs by ¢ltration through a nitrocellulose ¢lter (Millipore,
Bedford, MA, USA), followed by washing with bu¡er B three times.
The RNA molecules were eluted from the ¢lter as described [24]. To
eliminate the RNA species that bind to the ¢lter, the RNAs were
passed through the ¢lter prior to ampli¢cation [29].
2.3. Cloning and sequencing
The PCR product of the 21st round of selection was digested with
the EcoRI and PstI endonucleases, subcloned into pUC119, and then
transformed into E. coli MV1190. The plasmid DNA was isolated by
alkaline lysis and was sequenced by a dye terminator method (Applied
Biosystems) on an automatic sequencer (model 377, Applied Biosys-
tems).
2.4. Nitrocellulose ¢lter-binding assay
The RNAs were transcribed from the PCR products by T7 RNA
polymerase (Epicenter Technologies) with [K-32P]UTP (3000 Ci/
mmol; Amersham Pharmacia Biotech). The renatured RNA (0.8
WM) and the protein (0.8 WM) were incubated in 60 Wl of bu¡er A
at 37‡C for 60 min. A portion (50 Wl) of the solution was applied to
the pre-wetted nitrocellulose ¢lter under gentle vacuum and the ¢lter
was washed with 200 Wl of bu¡er B three times.
For the determination of the dissociation constant, Kd, 1.6 nM of
the 5P-labeled RNA was incubated with various concentrations (50^
1250 nM) of proteins. The amount of radioactivity on the ¢lter was
measured with a Bio-imaging analyzer (Fuji BAS 2500). The Kd was
calculated by using the Kaleidagraph software (Abelbeck Software,
Reading, PA) [24].
2.5. Competition assay
The Raf-1 GST-RBD (25 pmol), in 160 Wl of bu¡er A containing
0.05% Triton X-100, was mixed with 10 Wl of the matrix (glutathione-
Sepharose 4B) suspended in phosphate-bu¡ered saline (50% slurry).
The mixture was incubated at 4‡C for 30 min. After brief centrifuga-
tion, the supernatant was discarded. Then, the matrix was mixed with
Ras (2 pmol), which had been complexed with either GTPQS or GDP
as described previously [3], and was incubated with the renatured
RNAs (0^12.5 WM) in bu¡er A (160 Wl) at 4‡C for 30 min. After
the incubation, the matrix was washed with 500 Wl of bu¡er B three
times. The proteins were eluted from the matrix by denaturation with
Laemmli’s bu¡er and were fractionated by 15% SDS-PAGE. The
immunoblots were probed with the anti-Ras antibody RAS004 [30]
and were visualized by using the ECL immunodetection system
(Amersham Pharmacia Biotech).
3. Results
3.1. Isolation of RNA aptamers to the Raf-1 RBD
To focus on the isolation of aptamers that speci¢cally in-
hibit the interaction between Raf-1 and Ras, we utilized the
Ras-binding domain (GST-RBD) of Raf-1 as a selection tar-
get. Since the RBD is a basic protein, it binds to RNAs non-
speci¢cally at low ionic strength. The non-speci¢c binding of
the RNA pool to the protein decreased by increasing the salt
concentration. Consequently, a phosphate bu¡er containing
137 mM NaCl was used as the binding bu¡er for selection.
In vitro selection was started with a pool of RNAs containing
a random 60-nucleotide sequence (Fig. 1). The number of
RNA species present in the initial (round 0) pool was esti-
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Fig. 1. Starting RNA pool and the PCR primers used for in vitro
selection.
Fig. 2. Sequences in the random region of the RNAs from the pool in the 21st round. The entire RNA includes the 5P- and 3P-de¢ned sequen-
ces, as designated in Fig. 1. The RNA clones including the GUACAA(U)GGAUUCG sequences (underlined) are in the upper group. aThe
number in parentheses indicates the number of the same clone. bClone 21.08 has two point mutations in the de¢ned sequences. cThe binding
ratios of the RNAs to the Raf-1 GST-RBD were measured by a nitrocellulose ¢lter-binding assay.
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mated to be 8U1013, and about 10 copies of each RNA spe-
cies were included in the pool. Selection was ¢rst carried out
by immobilization of the protein-RNA complexes on the glu-
tathione-Sepharose 4B matrix. After 13 rounds of selection,
the binding ratio of the RNA pool was 0.36%. Accordingly,
further selection was continued using nitrocellulose ¢lter im-
mobilization instead of the aforementioned matrix. In addi-
tion, we raised the selection temperature from 4‡C to 37‡C,
considering our future plan to use the RNA aptamers as com-
petitive inhibitors of the Ras-Raf interaction in vivo. As a
result, the binding ratio of the 21st round pool was su⁄ciently
increased, to 28%.
The sequences of 33 clones isolated from the 21st pool were
determined, and 24 di¡erent clones were obtained (Fig. 2).
The interactions of 10 RNA clones with the Raf-1 GST-
RBD were examined by the nitrocellulose ¢lter-binding assay
(Fig. 2). The RNA clones were separated into two groups.
The binding ratios of clones 21.01^21.09 were over 10%, while
the other RNA clones only weakly bound to the Raf-1 GST-
RBD (6 3%). The Kd values of 21.01 and 21.07 were deter-
mined to be 332 þ 93 nM, and that of 21.11 was in the micro-
molar range (Fig. 3). The 21.01, 21.05, 21.07, 21.08, and 21.09
RNAs did not bind to GST by itself, indicating that these
RNAs bind to the Raf-1 RBD moiety rather than the GST
moiety. Seven sequences, 21.01^21.07, were probably derived
from a single parental clone that accumulated mutations dur-
ing the PCR ampli¢cation. The nine tightly binding clones,
21.01^21.09, were found to have in common a partial se-
quence of GUACAAUGGAUUCG, except that 21.09 lacks
the central U. This conserved sequence, GUACAAUG-
GAUUCG, was not found in the sequences of the weakly
binding clones, 21.10^21.24. The Mulfold program was used
to generate possible secondary structures of the RNAs [31].
RNAs 21.01^21.09 extensively form base pairs, involving both
the variable and constant regions (Fig. 4). The GUA-
CAA(U)GGAUUCG motif is located in the same internal
loop and stem structure (Fig. 4).
3.2. Inhibition of Raf-1 RBD binding to Ras by RNA aptamers
We examined whether these RNA aptamers can interfere
with the interaction between Ras and the Raf-1 RBD. Indi-
vidual RNAs (21.01, 21.07, 21.11, and 21.12), ranging in con-
centration from 0 to 12.5 WM, and the GTPQS-bound or
GDP-bound Ras were incubated with the Raf-1 GST-RBD
immobilized on the Sepharose matrix. The binding of Ras to
the Raf-1 GST-RBD in the presence and absence of RNAs
was detected by immunoblotting with the anti-Ras antibody,
RAS004 (Fig. 5, upper panels). RNAs 21.01 and 21.07 e¡ec-
tively decreased the binding between Ras and the Raf-1 RBD
(Fig. 5A,B). The RNA concentrations required for the inhib-
itory e¡ects are consistent with the tight binding of the Raf-1
RBD and the GTP-bound Ras [14]. These RNAs exhibited no
a⁄nity for either the GTP-bound Ras (Fig. 3) or the Sephar-
ose matrix (data not shown). In contrast, the weakly binding
RNAs, 21.11 and 21.12, had no inhibitory e¡ect on the bind-
ing of Ras to the Raf-1 GST-RBD, even when an excess
amount was added (Fig. 5C,D). Thus, the inhibitory e¡ects
correlate with the binding abilities of these RNA aptamers to
the Raf-1 RBD.
For selective inhibition of the Ras-Raf interaction, the
RNA aptamers must speci¢cally bind to Raf-1, but not to
either the other various downstream e¡ector molecules or
Ras. Thus, we examined the interactions of the RNA ap-
tamers (21.01, 21.05, 21.07, 21.08, and 21.09) with another
downstream e¡ector, the Ras-binding domain (amino acid
residues 632^734) of RGL (RalGDS-like) in the GST-fusion
form [26]. The binding ratios of these RNA aptamers were all
lower than 0.2% (Fig. 3), indicating that the aptamers sharply
discriminate between the two di¡erent downstream e¡ectors
of Ras. In addition, since these RNA aptamers did not bind
to Ras (Fig. 3), they only inhibit the interaction between Ras
and Raf-1, with no e¡ects on those between Ras and other
e¡ectors.
FEBS 21319 21-12-98
Fig. 3. Binding curves of the cloned RNAs with the proteins (b, a,
P, and U : 21.01 with the Raf-1 GST-RBD, the RGL GST-RBD,
GST, and the GTP-bound Ras, F : 21.07 with the Raf-1 GST-RBD,
R : 21.11 with the Raf-1 GST-RBD). Data points were obtained by
the nitrocellulose ¢lter-binding assay.
Fig. 4. Predicted secondary structure of 21.01 (A) and 21.09 (B).
The 5P- and 3P-de¢ned sequences are shown in lower-case letters.
The random regions are shown in bold letters. The conserved se-
quence is enclosed.
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4. Discussion
The RNA aptamers that we isolated bind to the Raf-1
RBD, but not to the RGL RBD, and competitively inhibit
the Ras-Raf interaction. The binding site for these aptamers
on the Raf-1 RBD is likely to be at or near the binding inter-
face for Ras, although they could possibly interact with other
regions of the Raf-1 RBD. The amino acid residues involved
in the interface between the Raf-1 RBD and Ras have been
identi¢ed by mutation analyses [32,33], and also from the
crystal structure of the complex between the Ras-like mutant
Rap1A and the Raf-1 RBD [34]; several Raf-1 RBD residues,
such as Arg-59, Lys-84, and Arg-89, are located in an K-helix
and the L-strands of a ubiquitin-like fold [35], and interact
with several Ras residues, such as Glu-31, Asp-33, Glu-37,
and Asp-38, in the ‘e¡ector region’. These RNA aptamers
to the Raf-1 RBD discriminate against the RGL RBD with
a low sequence homology. On the other hand, the Ras-bind-
ing domain of RalGDS (a homolog of RGL) is in the ubiq-
uitin-like fold, which is nearly the same as that of the Raf-1
RBD, and displays similar amino acid residues in the regions
corresponding to the Ras-binding interface of the Raf-1 RBD
[36^38]. These structural features are well conserved in the
RGL RBD (unpublished results). Nevertheless, the slight dif-
ferences in the interface residue arrangement between the Raf-
1 RBD and the RGL and RalGDS RBDs [34,38] are likely to
be recognized by the present RNA aptamers. Intriguingly, the
Raf-1 RBD and Ras are rich in positively charged residues
and negatively charged residues, respectively, with respect to
their binding interfaces, as described above. Therefore, the
negative charges of the RNA aptamers might be involved in
the interaction with the Raf-1 RBD. In this context, it has
been reported that RNA aptamers to thrombin, vascular en-
dothelial growth factor, and basic ¢broblast growth factor,
bind to their target proteins competitively with electronegative
heparin, suggesting that these aptamers interact with the elec-
tropositive heparin-binding site [39^41].
The aptamers to the Raf-1 RBD may be used to speci¢cally
inhibit the Ras-Raf interaction in the complicated signaling
network in cells, without a¡ecting other downstream e¡ectors
of Ras. The anti-Raf-1 aptamers would be delivered through
the cell membrane, or transiently expressed in the cell, as
reported for RNA aptamers to HIV Rev [42]. The anti-Raf-
1 aptamers may also be potential diagnostic and therapeutic
tools targeting the interaction between two proto-oncogene
products, Ras and Raf-1, as in the cases of aptamers to hu-
man neutrophil elastase used in in vivo imaging of in£amma-
tion [43] and in RNA therapy for lung in£ammatory injury
[44].
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